Spots Global Cancer Trial Database for trastuzumab
Every month we try and update this database with for trastuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years | NCT01480674 | Breast Cancer | Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery | NCT00381901 | Breast Cancer | trastuzumab polymorphism an... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | NCT01764022 | Human Epithelia... | Trastuzumab Paclitaxel | 18 Years - 75 Years | Biocad | |
| Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO) | NCT01160094 | Cancer | Treatment | 18 Years - | Novartis | |
| Cardiac Safety Study in Patients With HER2 + Breast Cancer | NCT01904903 | HER2 Positive B... Left Ventricula... | Trastuzumab Pertuzumab Ado Trastuzumab... | 18 Years - 120 Years | Medstar Health Research Institute | |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | NCT02954536 | Esophageal Canc... Gastric Cancer | pembrolizumab trastuzumab capecitabine cisplatin Oxaliplatin 5-Fluorouracil | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | NCT00401427 | Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | National Cancer Institute, Naples | |
| PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | NCT00216047 | Breast Cancer | PTK787 Trastuzumab | 18 Years - | Hoosier Cancer Research Network | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | NCT06253871 | HER2 Mutation-R... | IAM1363 Trastuzumab | 18 Years - | Iambic Therapeutics, Inc | |
| BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors | NCT05555251 | HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast... | BI-1607 BI-1607 Trastuzumab | 18 Years - | BioInvent International AB | |
| Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer | NCT00712140 | Breast Cancer | trastuzumab parenteral chem... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer | NCT03728829 | Observational Prospective | Trastuzumab+TP | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | NCT01125566 | Breast Neoplasm... | BIBW 2992 trastuzumab vinorelbine vinorelbine | 18 Years - | Boehringer Ingelheim | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| The Synergism Or Long Duration (SOLD) Study | NCT00593697 | Breast Neoplasm... | trastuzumab (9 ... trastuzumab (9 ... | 18 Years - | Finnish Breast Cancer Group | |
| GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | NCT00085020 | Breast Cancer | trastuzumab lapatinib ditos... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| NSABP Biospecimen Discovery Project | NCT01850628 | Breast Cancer | Paclitaxel trastuzumab pertuzumab | 18 Years - | NSABP Foundation Inc | |
| Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | NCT00968968 | Cancer | Lapatinib Trastuzumab | 18 Years - | Novartis | |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | NCT02827877 | HER2 Positive B... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Copper Cu 64-DO... Laboratory Biom... Pertuzumab Positron Emissi... Therapeutic Con... Trastuzumab | 18 Years - | City of Hope Medical Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | NCT02598310 | Breast Cancer Estrogen Recept... HER-2 Positive ... | nab-paclitaxel Trastuzumab | 20 Years - 70 Years | Osaka Medical College | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pre Operative Trastuzumab in Operable Breast Cancer | NCT01785420 | Carcinoma Breas... HER2 Positive B... | Trastuzumab Placebo | 18 Years - 80 Years | Tata Memorial Hospital | |
| microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin | NCT02656589 | Breast Cancer | Capecitabine Trastuzumab | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| STOP Heart Disease in Breast Cancer Survivors Trial | NCT02674204 | Breast Cancer Heart Disease Cardiotoxicity Myocardial Dysf... | Atorvastatin Placebo | 18 Years - | Cedars-Sinai Medical Center | |
| A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | NCT01491737 | Breast Cancer | Pertuzumab Trastuzumab Aromatase Inhib... Induction Chemo... | 18 Years - | Hoffmann-La Roche | |
| Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery | NCT00381901 | Breast Cancer | trastuzumab polymorphism an... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | NCT01235897 | Advanced Solid ... Tumors Cancer | MK-2206 Paclitaxel Trastuzumab | 18 Years - | University of California, San Francisco | |
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | NCT05188313 | Esophageal Canc... Esophageal Aden... | Trastuzumab Pertuzumab Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | NCT01423123 | Breast Cancer | Paclitaxel trastuzumab Neratinib | 18 Years - | NSABP Foundation Inc | |
| Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | NCT05193292 | Colorectal Neop... Intestinal Neop... | Camrelizumab Trastuzumab XELOX regimen mFOLFOX6 regime... FOLFIRI regimen mXELIRI regimen mIRIS regimen | 18 Years - | Fudan University | |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | NCT05318339 | Carcinoma, Tran... HER-2 Gene Ampl... | Trastuzumab | 18 Years - | ChineseAMS | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | NCT01940497 | Breast Cancer | Doxorubicin Docetaxel Paclitaxel Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Analysis of Brain Metastasis in Patients With Lung Cancer | NCT00071344 | Carcinoma, Non-... | - | National Institutes of Health Clinical Center (CC) | ||
| Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | NCT01875666 | Breast Neoplasm... | Trastuzumab pertuzumab lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | NCT00005635 | Breast Cancer | trastuzumab paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | NCT04419181 | HER2-positive B... | Docetaxel Carboplatin Trastuzumab Pertuzumab Trastuzumab emt... | 18 Years - | University of Rochester | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | NCT02006667 | Urinary Tract C... | trastuzumab gemcitabine cisplatin | 18 Years - | Hoffmann-La Roche | |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | NCT04253561 | Metastatic Brea... | Ipatasertib Trastuzumab Pertuzumab | 18 Years - | SOLTI Breast Cancer Research Group | |
| Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | NCT00317720 | Breast Cancer Neoplasm Metast... | Trastuzumab RAD001 | 18 Years - | M.D. Anderson Cancer Center | |
| Trastuzumab in Treating Patients With Prostate Cancer | NCT00003740 | Prostate Cancer | trastuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | NCT02252887 | Metastatic HER2... | Gemcitabine Trastuzumab Pertuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients | NCT02910219 | Breast Cancer | Crofelemer | 18 Years - | Georgetown University | |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | NCT03680560 | Solid Tumor HER-2 Protein O... | ACTR T Cell Pro... Trastuzumab | 18 Years - 75 Years | Cogent Biosciences, Inc. | |
| Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | NCT00615602 | Breast Cancer | Docetaxel Trastuzumab Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... Trastuzumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | NCT01690325 | Breast Cancer | Docetaxel Trastuzumab Bevacizumab Epirubicin Cyclophosphamid | 18 Years - 65 Years | West German Study Group | |
| Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | NCT00303992 | Breast Cancer | trastuzumab irinotecan hydr... | - 120 Years | University of California, San Francisco | |
| Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | NCT00004013 | Breast Cancer | trastuzumab paclitaxel | - | Fred Hutchinson Cancer Center | |
| Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00016367 | Lung Cancer | Trastuzumab Cisplatin Gemcitabine Hyd... | 18 Years - | M.D. Anderson Cancer Center | |
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | NCT00134680 | Metastatic Brea... | Letrozole Trastuzumab | 18 Years - | Duke University | |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | NCT01008150 | Breast Cancer | Paclitaxel Trastuzumab Neratinib Doxorubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | NCT01106898 | Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... | cyclophosphamid... paclitaxel trastuzumab laboratory biom... | 20 Years - | University of Nebraska | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | NCT03125928 | HER2-positive B... | Atezolizumab Paclitaxel Trastuzumab Pertuzumab | 18 Years - | Fox Chase Cancer Center | |
| Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | NCT01901146 | Breast Cancer | ABP 980 Trastuzumab Paclitaxel Lumpectomy or M... | 18 Years - | Amgen | |
| NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer | NCT02030561 | Breast Cancer Gastric Cancer | Trastuzumab + N... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | NCT01254136 | Breast Cancer | INCB007839 300m... Trastuzumab Vinorelbine | 18 Years - | Incyte Corporation | |
| Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive | NCT01503983 | Stage IV Gastri... | Trastuzumab Capecitabine Oxaliplatin | 18 Years - | Fundación para el Progreso de la Oncología en Cantabria | |
| A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | NCT01966471 | Breast Cancer | Trastuzumab Emt... Trastuzumab Pertuzumab Paclitaxel Epirubicin Doxorubicin Docetaxel Cyclophosphamid... 5-Fluorouracil | 18 Years - | Hoffmann-La Roche | |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer | NCT02004769 | Stomach Neoplas... Neoplasms Metas... ERBB2 Gene Ampl... | Trastuzumab Docetaxel Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer | NCT01142778 | Breast Cancer | Bevacizumab Docetaxel Trastuzumab Surgery Radiotherapy Hormonal Therap... | 18 Years - | Hoffmann-La Roche | |
| Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | NCT05228951 | Breast Cancer | Pyrotinib malea... | 18 Years - 75 Years | Shengjing Hospital | |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | NCT04120246 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Refractory Brea... | Alpha-tocophery... Trastuzumab | 18 Years - | Veana Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
